aureus enterocolitis, and no one challenged its validity. On the basis of this assumption, oral vancomycin became the standard treatment and seemed to work well [4] . The first study to seriously question the etiologic role of S. aureus in antibiotic-associated colitis was the report by Tedesco et al. in 1974 [5] . Tedesco, a gastroenterologist at Barnes Hospital, was struck by the large number of patients with antibiotic-associated colitis as an adverse effect of treatment with clindamycin, which had become a favored drug for treatment of anaerobic infections during the "anaerobic bandwagon." The Barnes investigators then performed a prospective evaluation of 200 patients treated with clindamycin; 41 (21%) developed diarrhea, and 20 (10%) had PMC detected by use of endoscopy. Theirs was the first report in which endoscopy had been routinely performed in patients with antibiotic-associated diarrhea, and the observation of a 10% frequency of PMC shocked the medical community, since this was viewed as a potentially lethal adverse effect of treatment with antibiotics. One of the important observations was the absence of S. aureus, despite the relative ease of growing this organism in selective cultures.
The second series of contributing experiments concerned the rodent model of antibiotic-associated colitis. Hambra et al. [6] attempted to show the potential value of penicillin in the treatment of gas gangrene in a guinea pig model, in an effort to treat this infection after battle injuries in World War II. However, treatment with penicillin proved to be more lethal than gas gangrene in the guinea pig model; necropsy studies showed large ceca filled with hemorrhagic fluid. Subsequent work showed that guinea pigs were susceptible to a multitude of antibiotics that also proved to be lethal to hamsters. The reason for penicillin-associated deaths in these rodents remained a mystery in veterinary medicine but, fortunately, did not deter the subsequent development of penicillin for humans. There were many attempts to define the mechanism, but a particularly important one was reported in 1974 by Green [7] , who noted that stools and tissues of affected animals showed cytotoxic changes in tissue-cultured cells, suggesting that a viral infection was present, although no virus could be propagated. They concluded that antibiotic-associated cecitis in rodents was due to a latent virus.
The third line of relevant investigations concerned studies of C. difficile. This organism was first recognized as a component of the normal intestinal flora of newborn infants by Hall and O'Toole in 1935 [8] . They noted that the organism, which was known at the time as "Bacillus difficilis," because of its fastidious growth requirements, produced a toxin in vitro that was highly lethal when injected intraperitoneally in mice. Potency was impressive; in the mouse lethality test, it was just 1-2 logs lower than botulinum toxin [9] . Nevertheless, there did not appear to be any clinical consequences in humans, because its presence in stool or even at infected sites was not associated with any defined histotoxic clostridial syndrome. The conclusion was that either the organism did not produce the toxin in vivo or humans were not susceptible. One of the most comprehensive reports of C. difficile was written by Hafiz at the University of Leeds, who completed his PhD thesis on it [10] . His report showed that the organism was a common component of the stool flora in many different animals, including camels, that it was widespread in the environment, and that most strains were toxigenic.
This review of data along these 3 lines of investigation shows that all 3 culminated in what might be viewed retrospectively as seminal reports in 1974; at the time, there was no way of knowing that the organism so comprehensively studied by Hafiz [10] produced the cytotoxin discovered by Green [7] that caused the complication so elegantly described in the colonoscopy studies of Tedesco et al. [5] .
My own interest in this topic was based on my fellowship experience with Sydney Finegold, who fostered general interest in anaerobic infections. One of my projects was the first large prospective study of lincomycin for treatment of anaerobic infections [11] , a clinical trial that Upjohn refused to support because the physicians they queried in Kalamazoo, Michigan, had never heard of anaerobic infections. Despite extensive use of lincomycin and, then, clindamycin, I had not witnessed the devastating complication of "clindamycin colitis" reported in 10% of all clindamycin recipients by Tedesco et al. [5] . In retrospect, this phenomenon is probably best explained by an epidemic of C. difficile at Barnes Hospital, but the epidemic was certainly not recognized at the time. Sherwood Gorbach encouraged me to pursue this as a new line of investigation using the animal model, with the goal of identifying an enteric pathogen in the model without the tedious process of culturing the stool. The 1977 publication in The Journal of Infectious Diseases was the result of those experiments.
Syrian hamsters were challenged with clindamycin and, predictably, developed florid cecitis that proved to be lethal, usually within 3-5 days. Cecal contents were aspirated and inoculated intracecally into a hamster that had not been treated with clindamycin. The procedure was repeated for 5 serial passages. Controls were hamsters that received intracecal injections from cecal contents of healthy hamsters. After the second passage, the cecal contents from 10 hamsters were pooled and centrifuged at 15,000 g for 30 min, the supernatant was removed, and aliquots were filtered with a 0.45-mm filter, a 0.02-mm filter, and a PM-10 membrane filter. Those experiments showed that the cecal contents from clindamycin-treated hamsters produced typical cecitis with 5 serial passages. All hamsters died within 3 days. The transferable agent passed through the 0.02-mm filter but was retained by the PM-10 membrane filter, indicating that the toxin was filterable.
The next series of experiments included efforts to neutralize the toxin. Multiple trials were performed, but the one that worked was performed with gas gangrene antitoxin. On the basis of this information, stool was cultured, using heat shock to select for clostridia. Several clostridia were recovered and grown in broth culture, and then the supernatant was used for intracecal injection. One strain reproduced this disease. The experiment was reproducible with intracecal challenge in 16 of 16 recipients, and neutralization was achieved with gas gangrene antitoxin. The implicated Clostridium species was then cultured from each of 5 hamsters with clindamycin-induced disease and was recovered in concentrated 10 8 -10 9 cfu/g of dry weight. The identity of this Clostridium species was unclear, and it was consequently named in the report by the appellation that it had acquired in the laboratory: Clostridium BVA 17 HF1-9. "BVA" represented the Boston VA Hospital where the work was done, "17 HF" indicated the experiment in this series of studies in which each series of experiments was given "H" for hamster and a letter until the alphabet was complete, then going to the second numerical designation. Thus, "17F" indicated that this was experiment number 442, and "1-9" indicated that this Clostridium species was the ninth cecal isolate tested in the first hamster of that series.
The conclusion from this series of experiments was that antibiotic-associated colitis was caused by a toxin produced by Clostridium BVBA 17 HF1-9. Andy Onderbonk was pretty sure it was C. difficile, but an attempt to confirm this in Sydney Finegold's lab was frustrated by contamination, and we decided that we needed to go to press, because Bob Fekety and colleagues, our competition in these studies, was believed to be not far behind.
Once the cause of antibiotic-associated entercolitis was defined in the rodent model, it was critical to link this to clinical observations by identifying the same agent in cases of antibioticassociated colitis in humans. There were 2 facets to the immediate work in this area that are highly relevant. The first is the work of T. W. Chang, a collaborator in the Infectious Disease Division at Tufts University. He was convinced that the etiology of antibiotic-associated colitis was viral, had pursued tissue-culture assays, and had found a cytopathic effect with the highly characteristic actinomorphic changes in all fibroblast cell lines, as previously reported by Green [7] . However, when no virus could be propagated, Chang showed that the cytotoxin could be neutralized by gas gangrene antitoxin, which fit well with our observations in the hamster model. This antitoxin is composed of antibodies to the 5 clostridia toxins implicated in gas gangrene, so the next step was to define which of the 5 clostridia toxins implicated in gas gangrene was responsible for neutralization. The results of that experiment showed that it was C. sordelli antitoxin. However, C. sordelli could not be cultivated from the hamster, and BVA 17 HF1-9 produced a toxin in vitro that was neutralized by this antitoxin, indicating that antigenic cross-reaction had occurred. The next experiment was the use of this diagnostic test on stool specimens from patients with antibioticassociated colitis, and the report of 4 such cases was published in 1978 [12] .
With the detection of a new microbe in human disease, the usual cascade of subsequent studies includes the development of a diagnostic test for recognition, use of this test to define the clinical spectrum, investigations of pathophysiology, and attempts at treatment and prevention. This work was done in 1978 to 1980 and included the initial report of 2 toxins produced by C. difficile, now designated toxin A and toxin B [13] . Studies of the carriage rate [14] , the implications of multiple antibiotics causing this complication [15] , the serologic response to toxin A and B [16] , the definition of the clinical spectrum [17] , the definition of the cytotoxic assay that became the routine test for that period [18] , and the first report of the enzyme immunoassay [19] followed.
In 1980, it appeared to me that most of the important work in this area had been done and that it was time to move on. Nevertheless, multiple other investigators have subsequently substantially advanced this field. Bob Fekety and his colleagues at the University of Michigan made important contributions in the early years doing work that, in retrospect, was very similar to the work from our laboratory in Boston. Recent work by multiple groups has provided a better definition of the pathophysiology of PMC, has shown the importance of C. difficile as a nosocomial pathogen, and has improved diagnostic testing with alternatives to the cumbersome cytotoxic assay (although no test has matched tissue culture for sensitivity). Metronidazole has become the preferred antibiotic for treatment of C. difficile infection, and multiple relapses are now recognized as one of the major challenges to treatment. Vaccines are now being explored as a method of prevention.
At the present time, C. difficile is recognized as one of the most important enteric bacterial pathogens in the developed world. Clinical expression is tightly linked to exposure to antibiotics, diagnostic testing is readily available and reasonably sensitive, and metronidazole therapy is generally highly effective and inexpensive. In retrospect, it is important to acknowledge that most of the important clinical observations were initially made in a hamster model, including detection of the etiologic agent, discovery of the implicated antibiotics, development of the diagnostic test, and treatment with oral vancomycin. This hamster model proved to be exceptionally valuable in providing insights into human disease.
